Serum retinol and HIV-1 RNA viral load in rapid and slow progressors. 1998

W L Camp, and S Allen, and J O Alvarez, and P E Jolly, and H L Weiss, and J F Phillips, and E Karita, and A Serufilira, and S H Vermund
Schools of Public Health, University of Alabama at Birmingham, 35294-0008, USA.

Few studies have addressed the relation between serum vitamin A level and HIV disease progression. Thirty HIV-infected women in Rwanda were studied over a time span of 26 to 99 months. Fourteen subjects seroconverted and died of HIV-related disease at a mean of 44 months (range, 26-69 months) after their first HIV-positive test and were termed "rapid progressors," (RPs). A comparison group of 16 "slow progressors" (SPs) were HIV-positive at the time of their first HIV serology and had asymptomatic HIV infections at a mean of 96 months (range, 93-99 months) after their first HIV serology. Baseline mean serum retinol values were the same in RPs and SPs: 0.65 + 0.08 mmol/L versus 0.67 + 0.09 micromol/L (p = .7). Lower serum retinol levels were observed in RPs compared with SPs for the second and third measurements, obtained at a median of 12 and 24 months past baseline: 0.51 + 0.07 mmol/L versus 0.76 + 0.14 mmol/L (p = .3) and 0.44 + 0.09 mmol/L versus 0.64 + 0.08 mmol/L (p = .08), respectively. Median retinol levels for the third sample measurement were similar in RPs with lower viral load (LVL) and SPs (0.49 mmol/L and 0.52 mmol/L, respectively) compared with only 0.19 mmol/L in RPs with higher viral load (HVL; p = .02). A trend toward decreasing serum retinol levels and increasing HIV-1 RNA viral load was observed at the third sample measurement (p = .04). Subjects with LVL, higher serum retinol levels (> or =0.70 mmol/L), or both had more favorable rates of survival than subjects with HVL, low serum retinol levels (<0.70 mmol/L), or both. Although sample size does not permit definitive conclusions, this study demonstrates an association of high HIV load, rapid progression, and low serum retinol late but not early in disease progression.

UI MeSH Term Description Entries
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D012432 Rwanda A republic in eastern Africa, south of UGANDA, east of DEMOCRATIC REPUBLIC OF THE CONGO, west of TANZANIA. Its capital is Kigali. It was formerly part of the Belgian trust territory of Ruanda-Urund. Ruanda,Republic of Rwanda
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014801 Vitamin A Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products. Retinol,11-cis-Retinol,3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer,All-Trans-Retinol,Aquasol A,Vitamin A1,All Trans Retinol
D014802 Vitamin A Deficiency A nutritional condition produced by a deficiency of VITAMIN A in the diet, characterized by NIGHT BLINDNESS and other ocular manifestations such as dryness of the conjunctiva and later of the cornea (XEROPHTHALMIA). Vitamin A deficiency is a very common problem worldwide, particularly in developing countries as a consequence of famine or shortages of vitamin A-rich foods. In the United States it is found among the urban poor, the elderly, alcoholics, and patients with malabsorption. (From Cecil Textbook of Medicine, 19th ed, p1179) Deficiency, Vitamin A,Deficiencies, Vitamin A,Vitamin A Deficiencies
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

W L Camp, and S Allen, and J O Alvarez, and P E Jolly, and H L Weiss, and J F Phillips, and E Karita, and A Serufilira, and S H Vermund
July 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
W L Camp, and S Allen, and J O Alvarez, and P E Jolly, and H L Weiss, and J F Phillips, and E Karita, and A Serufilira, and S H Vermund
February 2000, International journal of STD & AIDS,
W L Camp, and S Allen, and J O Alvarez, and P E Jolly, and H L Weiss, and J F Phillips, and E Karita, and A Serufilira, and S H Vermund
September 2002, Clinics in laboratory medicine,
W L Camp, and S Allen, and J O Alvarez, and P E Jolly, and H L Weiss, and J F Phillips, and E Karita, and A Serufilira, and S H Vermund
April 1995, Lancet (London, England),
W L Camp, and S Allen, and J O Alvarez, and P E Jolly, and H L Weiss, and J F Phillips, and E Karita, and A Serufilira, and S H Vermund
October 2022, Journal of acquired immune deficiency syndromes (1999),
W L Camp, and S Allen, and J O Alvarez, and P E Jolly, and H L Weiss, and J F Phillips, and E Karita, and A Serufilira, and S H Vermund
February 2000, The Australian & New Zealand journal of obstetrics & gynaecology,
W L Camp, and S Allen, and J O Alvarez, and P E Jolly, and H L Weiss, and J F Phillips, and E Karita, and A Serufilira, and S H Vermund
January 2017, PloS one,
W L Camp, and S Allen, and J O Alvarez, and P E Jolly, and H L Weiss, and J F Phillips, and E Karita, and A Serufilira, and S H Vermund
September 1996, AIDS (London, England),
W L Camp, and S Allen, and J O Alvarez, and P E Jolly, and H L Weiss, and J F Phillips, and E Karita, and A Serufilira, and S H Vermund
August 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
W L Camp, and S Allen, and J O Alvarez, and P E Jolly, and H L Weiss, and J F Phillips, and E Karita, and A Serufilira, and S H Vermund
May 1999, The Journal of infection,
Copied contents to your clipboard!